The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. - Wikidata - wikimedia - TriplyDB

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

http://www.wikidata.org/entity/Q46549173

about

PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12 Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies Inflammatory etiopathogenesis of systemic lupus erythematosus: an update Animal models of anti-neutrophil cytoplasmic antibody-associated vasculitis Intracellular nucleic acid sensors and autoimmunity Small molecules in the treatment of systemic lupus erythematosus Autophagy in plasma cell pathophysiology Treatment options and strategies for antibody mediated rejection after renal transplantation Novel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat model Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.Emerging Therapies for Rheumatoid Arthritis Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha Identification of gp96 as a novel target for treatment of autoimmune disease in mice Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors The pathogenesis, diagnosis and treatment of lupus nephritis.Immunoproteasome overexpression underlies the pathogenesis of thyroid oncocytes and primary hypothyroidism: studies in humans and mice.Pno1 tissue-specific expression and its functions related to the immune responses and proteasome activities.Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis.Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes.Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome.Mechanisms of Autoantibody-Induced Pathology.Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target Immunomodulatory properties of stem cells from human exfoliated deciduous teeth Histopathologic insights into the mechanism of anti-non-Gal antibody-mediated pig cardiac xenograft rejection Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients Treatment of chronic graft-versus-host disease with bortezomib Bortezomib in kidney transplantation.Proteasome inhibitor bortezomib ameliorates intestinal injury in mice.Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation.The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature.Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model Murine models of systemic lupus erythematosus No evidence of pathogenic involvement of cathelicidins in patient cohorts and mouse models of lupus and arthritis Activation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome.A review of the mammalian unfolded protein response.

P2860

Q24323912-10F5D825-DD82-4E92-91F0-45E064C089CA Q26751959-673F3E5A-29B6-41F3-9E3E-319C51558C0B Q26796413-63AC1AB7-094E-4EB4-882A-30E32BB65E4E Q26864089-F6045904-2DC5-4461-B5E8-AA4B6EF5ECAF Q26997316-790B50FD-8BA8-46F8-B9DB-87820A39EBF8 Q27010090-A9420538-AC20-4774-8384-D0168F5EE6D5 Q27015920-468D9293-B858-4539-B14F-8441DB4D8425 Q27021397-AEA0F06E-C0B1-4960-A811-4BF84BEEFA87 Q27315858-FC523774-1783-4105-A8CE-F447EE36B728 Q27686770-A1079EF1-A8AF-460B-8A9D-CE08E2130ADF Q28078943-7CEA30D2-C2DE-4EA6-A1FC-CD01955A5561 Q28265144-6E0D8032-ED5B-4E9A-8FF3-DACF88DFAB81 Q28473392-C728C3DA-ACFA-4292-B6BB-DDD3E8A70F87 Q28730577-002EC1A2-9741-41D4-8721-4CF596B8D20C Q30596968-B91A6713-9321-4C25-A143-FD6C0A12C773 Q30894991-505EA0BA-3ED1-4C99-8079-FF9DB6297B62 Q31101725-A5265C02-98F5-4F96-9CD4-8091C7142BB9 Q33430998-2C64E6E3-D9B5-486E-9F6E-0FD3FC6E692B Q33438199-039BC5EC-3E74-4D55-B5BF-AD2ACECA4DAF Q33584895-AE698298-1036-4C18-83E1-4CBECF34AA8F Q33703372-A6877D22-49FB-413B-A47F-5DFA99B5F157 Q33715480-A25367D7-639D-46EA-B888-F34DE08BAFDA Q33740580-2B6B9779-46CA-486B-AEE5-B541E9D2FC2E Q33842215-680B6DD4-DDA9-4168-BEDF-DDBBF32AEA1C Q33865256-0B7D84A9-B604-40CE-8856-562B12C6DD21 Q34018912-2703CD93-FD7C-40DC-B422-180070A3B5AE Q34085747-84E338FD-E139-46D6-89CF-31A9CD8D8BA2 Q34137032-678F96F8-6DA9-4F16-BD41-B870351F2B05 Q34189435-B5A1069B-F83A-4770-A923-C9776AA01F9A Q34222685-C3C343F7-0EA3-4A66-BBAA-2985C4581B91 Q34267100-ACD333BA-FE56-4630-8A5F-D4AADBF22713 Q34464260-EC91360A-8511-498F-9BA3-D6D6EBB43F6C Q34471099-85D863BF-DC7A-4F64-86EE-1E89DCF44698 Q34478543-EA3A8C67-3E1A-4313-A541-CEF3A70BA775 Q34591019-16C19FE8-E55F-4A10-A78D-19172CBB7FEF Q34764677-385A75F4-96B5-4848-9995-467357B83671 Q34773996-F0A018B1-B88A-4664-83F3-2248C9D59060 Q35070412-93D36D37-0B43-4A84-8A10-5A04B9525F56 Q35202606-ED180100-3599-40C4-8461-145974301D19 Q35354864-FFD08AF6-FCF5-4D46-85FA-F1D24AF17972

P2860

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

http://www.wikidata.org/entity/Q46549173

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

The proteasome inhibitor borte ...... s-like disease from nephritis.

@en

The proteasome inhibitor borte ...... s-like disease from nephritis.

@nl

type

label

The proteasome inhibitor borte ...... s-like disease from nephritis.

@en

The proteasome inhibitor borte ...... s-like disease from nephritis.

@nl

prefLabel

The proteasome inhibitor borte ...... s-like disease from nephritis.

@en

The proteasome inhibitor borte ...... s-like disease from nephritis.

@nl

P1433

Q46549173-ABFA5766-33B3-451B-AB52-5A335889F7D9

P1476

Q46549173-4818780C-38E9-4B1B-B125-A7F8AA736811

P2093

Q46549173-290DFC18-578B-4826-BE39-5D3AA5484985

Q46549173-3C91BC47-BA3D-4A2E-B37E-78E852CE707A

Q46549173-5C08B45E-EA69-4F37-8D09-2CBC197F12CD

Q46549173-6F64E2C0-202A-406E-AA7D-A9ED2BE14F49

Q46549173-855DE653-E966-4963-B1D8-BFBB3DA79F0D

Q46549173-8AA922C1-3F89-4180-9004-197FA1B0BC6F

Q46549173-B06B578B-802D-4E50-8391-CA08DA73C092

Q46549173-D02968B6-9FB9-4B1D-8DED-D9F467EF6DA1

Q46549173-E40E7DBB-F5C9-43F8-92C4-ED8EB438B5F8

Q46549173-F31088B8-627B-46F4-A585-068C14B01DFF

P2888

Q46549173-E6EF45E5-CF2A-425F-9280-8142EE8A7583

P304

Q46549173-A94F4B1C-AB64-460B-8C2C-267D60A5DFE6

P31

Q46549173-68670CFF-D00F-4918-BA1B-2FBE9B905B04

P356

Q46549173-3CFC5F44-2A9F-457B-A990-9F3BEFD26707

P407

Q46549173-13E85C12-11E8-489F-9F95-FE6F95FCDBAA

P433

Q46549173-189E1C18-EE6B-40B5-BB01-3E1C13D2B58C

P478

Q46549173-0A6C8BE9-A656-43B3-A6FF-2B1E00CF6BCC

P577

Q46549173-5E727EFA-6812-4896-91C0-C1837E2B85B5

P698

Q46549173-555A56BA-7286-4525-9A40-126A429AE936

P356

P1433

Nature Medicine

P1476

The proteasome inhibitor borte ...... s-like disease from nephritis.

@en

P2093

Carsten Wiethe

http://www.w3.org/2001/XMLSchema#string

Damian Maseda

http://www.w3.org/2001/XMLSchema#string

Florian Weisel

http://www.w3.org/2001/XMLSchema#string

Joachim R Kalden

http://www.w3.org/2001/XMLSchema#string

Katrin Moser

http://www.w3.org/2001/XMLSchema#string

Kerstin Amann

http://www.w3.org/2001/XMLSchema#string

Kirsten Neubert

http://www.w3.org/2001/XMLSchema#string

Reinhard E Voll

http://www.w3.org/2001/XMLSchema#string

Rudolf A Manz

http://www.w3.org/2001/XMLSchema#string

Silke Meister

http://www.w3.org/2001/XMLSchema#string

P2888

P304

748-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM1763

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18542049

http://www.w3.org/2001/XMLSchema#string